Patent classifications
A23V2400/51
Modified gram positive bacteria and uses thereof
The present invention relates to gram positive bacteria with increased stress resistance and/or improved storage characteristics. In particular, the invention relates to gram positive bacterium which accumulate intracellular trehalose. The gram positive bacterium according to the invention lack cellobiose-specific PTS system IIC component (PtcC) activity. The gram positive bacterium may further lack trehalose 6-phosphate phosphorylase (TrePP) activity. The gram positive bacterium may further overexpress trehalose transporters. The invention further relates to compositions comprising such gram positive bacterium as well as methods and uses thereof.
BIFIDOBACTERIA FOR TREATING CARDIAC CONDITIONS
This invention relates to new uses of Bifidobacteria (particularly, although not exclusively, probiotic Bifidobacteria), and to food products, feed products, dietary supplements and pharmaceutical formulations containing them. The bacteria are suitable for the treatment of myocardial infarction and congestive heart failure.
BIFIDOBACTERIA FOR TREATING CARDIAC CONDITIONS
This invention relates to new uses of Bifidobacteria (particularly, although not exclusively, probiotic Bifidobacteria), and to food products, feed products, dietary supplements and pharmaceutical formulations containing them. The bacteria are suitable for the treatment of myocardial infarction and congestive heart failure.
A COMBINATION PRODUCT FOR PROPHYLAXIS AND TREATMENT OF IRRITABLE BOWEL SYNDROME
A combination product comprising an isolated strain of Bifidobacterium NCIMB 41003 and another strain which does not adversely interact with Bifidobacterium NCIMB 41003 improves gastrointestinal symptoms associated with IBS and improves one or more of mood, stress, anxiety, sleep quality and depression associated with IBS.
A COMBINATION PRODUCT FOR PROPHYLAXIS AND TREATMENT OF IRRITABLE BOWEL SYNDROME
A combination product comprising an isolated strain of Bifidobacterium NCIMB 41003 and another strain which does not adversely interact with Bifidobacterium NCIMB 41003 improves gastrointestinal symptoms associated with IBS and improves one or more of mood, stress, anxiety, sleep quality and depression associated with IBS.
COMBINATION PRODUCT FOR PROPHYLAXIS AND TREATMENT OF IRRITABLE BOWEL SYNDROME
A combination product comprising a strain of Bifidobacterium NCIMB 41676 and a strain of Bifidobacterium NCIMB 41003 is used in the prophylaxis or treatment of irritable bowel syndrome (IBS). The combination product leads to a surprising, sustained positive effects, even after feeding has stopped.
Method for making ice cream with a low sugar content comprising prebiotics partly or totally fermented by probiotics
The invention relates to a process for formulating an ice cream wherein a high percentage of the added sugars (from 0% to 20%) is substituted for complex sugar substances known as prebiotics which, after pasteurization, can be partly or totally fermented by probiotic bacteria of the genera Bifidobacterium, Lactobacillus and Streptococcus, or hydrolyzed by enzymes to obtain a partly fermented ice cream with a low sugar content and containing a high number (>10.sup.6/ml) of live probiotic bacteria. The different prebiotics are used as individual ingredients or in mixtures and in diverse concentrations. The invention also relates to an ice cream comprising a reduced content of added sugars such as sucrose, dextrose, glucose syrup, partly or totally substituted for prebiotics, optionally fermented by probiotics and/or hydrolyzed by enzymes.
Programmable drug delivery profiles of tumor-targeted bacteria
The present invention relates to composition comprising at least one non-pathogenic bacterial cell, wherein the non-pathogenic bacterial cell comprises at least a first and a second nucleic acid sequence, the first nucleic acid sequence comprising at least one non-constitutive promoter operably linked to the second nucleic acid sequence that encodes therapeutic agent, wherein the non-constitutive promoter is an inducible promoter responsive to at least one stimuli and the at least one stimuli comprises the presence of a certain density or a certain number of bacterial cells comprising the first and second nucleic acid sequences.
THREE-LAYERED CAPSULE CONSTRUCTED WITH NON-HYDROGENATED OIL AND PRODUCTION THEREOF
The present invention is to inhibit the cracks of the protective layer when producing the three-layered capsules and to solve the problems of cracks when producing and storing in the cooled condition to provide a three-layered capsule and a production thereof without suck generation of cracks.
The present invention provides a three-layered capsule which comprises: a content comprising a main agent dispersed or solubilized in oil material, a protective layer, formed on the content, comprising edible refined and processed oil, and a shell, formed on an outside the protective layer, comprising natural polymer, the three layers being present concentrically, and a producing method of the capsule.
THREE-LAYERED CAPSULE CONSTRUCTED WITH NON-HYDROGENATED OIL AND PRODUCTION THEREOF
The present invention is to inhibit the cracks of the protective layer when producing the three-layered capsules and to solve the problems of cracks when producing and storing in the cooled condition to provide a three-layered capsule and a production thereof without suck generation of cracks.
The present invention provides a three-layered capsule which comprises: a content comprising a main agent dispersed or solubilized in oil material, a protective layer, formed on the content, comprising edible refined and processed oil, and a shell, formed on an outside the protective layer, comprising natural polymer, the three layers being present concentrically, and a producing method of the capsule.